Your browser doesn't support javascript.
loading
3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.
Jinsmaa, Yunden; Sharabi, Yehonatan; Sullivan, Patti; Isonaka, Risa; Goldstein, David S.
Afiliación
  • Jinsmaa Y; Clinical Neurocardiology Section, Clinical Neurosciences Program/Division of Intramural Research/National Institute of Neurological Disorders and Stroke/National Institutes of Health, Bethesda, Maryland (Y.J., Y.S., P.S., R.I., D.S.G.), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
  • Sharabi Y; Clinical Neurocardiology Section, Clinical Neurosciences Program/Division of Intramural Research/National Institute of Neurological Disorders and Stroke/National Institutes of Health, Bethesda, Maryland (Y.J., Y.S., P.S., R.I., D.S.G.), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
  • Sullivan P; Clinical Neurocardiology Section, Clinical Neurosciences Program/Division of Intramural Research/National Institute of Neurological Disorders and Stroke/National Institutes of Health, Bethesda, Maryland (Y.J., Y.S., P.S., R.I., D.S.G.), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
  • Isonaka R; Clinical Neurocardiology Section, Clinical Neurosciences Program/Division of Intramural Research/National Institute of Neurological Disorders and Stroke/National Institutes of Health, Bethesda, Maryland (Y.J., Y.S., P.S., R.I., D.S.G.), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
  • Goldstein DS; Clinical Neurocardiology Section, Clinical Neurosciences Program/Division of Intramural Research/National Institute of Neurological Disorders and Stroke/National Institutes of Health, Bethesda, Maryland (Y.J., Y.S., P.S., R.I., D.S.G.), and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
J Pharmacol Exp Ther ; 366(1): 113-124, 2018 07.
Article en En | MEDLINE | ID: mdl-29700232
The catecholaldehyde hypothesis posits that 3,4-dihydroxyphenylacetaldehyde (DOPAL), an obligate intermediary metabolite of dopamine, is an autotoxin that challenges neuronal homeostasis in catecholaminergic neurons. DOPAL toxicity may involve protein modifications, such as oligomerization of α-synuclein (AS). Potential interactions between DOPAL and other proteins related to catecholaminergic neurodegeneration, however, have not been systemically explored. This study examined DOPAL-induced protein-quinone adduct formation ("quinonization") and protein oligomerization, ubiquitination, and aggregation in cultured MO3.13 human oligodendrocytes and PC12 rat pheochromocytoma cells and in test tube experiments. Using near-infrared fluorescence spectroscopy, we detected spontaneous DOPAL oxidation to DOPAL-quinone, DOPAL-induced quinonization of intracellular proteins in both cell lines, and DOPAL-induced quinonization of several proteins related to catecholaminergic neurodegeneration, including AS, the type 2 vesicular monoamine transporter, glucocerebrosidase, ubiquitin, and l-aromatic-amino-acid decarboxylase (LAAAD). DOPAL also oligomerized AS, ubiquitin, and LAAAD; inactivated LAAAD (IC50 54 µM); evoked substantial intracellular protein ubiquitination; and aggregated intracellular AS. Remarkably, N-acetylcysteine, which decreases DOPAL-quinone formation, attenuated or prevented all of these protein modifications and functional changes. The results fit with the proposal that treatments based on decreasing the formation and oxidation of DOPAL may slow or prevent catecholaminergic neurodegeneration.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Acetilcisteína / Ácido 3,4-Dihidroxifenilacético / Proteínas Límite: Animals / Humans Idioma: En Revista: J Pharmacol Exp Ther Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Acetilcisteína / Ácido 3,4-Dihidroxifenilacético / Proteínas Límite: Animals / Humans Idioma: En Revista: J Pharmacol Exp Ther Año: 2018 Tipo del documento: Article